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Hereditary multiple exostoses (HME), a dominantly inherited genetic disorder characterized by multiple cartilag-
inous tumors, is caused by mutations in members of the EXT gene family, EXT1 or EXT2. The corresponding gene
products, exostosin-1 (EXT1) and exostosin-2 (EXT2), are type II transmembrane glycoproteins which form a
Golgi-localized heterooligomeric complex that catalyzes the polymerization of heparan sulfate (HS). Although the
majority of the etiological mutations in EXT are splice-site, frameshift, or nonsense mutations that result in pre-
mature termination, 12 missense mutations have also been identified. Furthermore, two of the reported etiological
missense mutations (G339D and R340C) have been previously shown to abrogate HS biosynthesis (McCormick
et al. 1998). Here, a functional assay that detects HS expression on the cell surface of an EXT1-deficient cell line
was used to test the remaining missense mutant exostosin proteins for their ability to rescue HS biosynthesis in
vivo. Our results show that EXT1 mutants bearing six of these missense mutations (D164H, R280G/S, and R340S/
H/L) are also defective in HS expression, but surprisingly, four (Q27K, N316S, A486V, and P496L) are pheno-
typically indistinguishable from wild-type EXT1. Three of these four “active” mutations affect amino acids that
are not conserved among vertebrates and invertebrates, whereas all of the HS-biosynthesis null mutations affect
only conserved amino acids. Further, substitution or deletion of each of these four residues does not abrogate HS
biosynthesis. Taken together, these results indicate that several of the reported etiological mutant EXT forms retain
the ability to synthesize and express HS on the cell surface. The corresponding missense mutations may therefore
represent rare genetic polymorphisms in the EXT1 gene or may interfere with as yet undefined functions of EXT1
that are involved in HME pathogenesis.
Introduction
Hereditary multiple exostoses (HME) (EXT [MIM
133700]) is an autosomal dominant bone disorder that
results in the formation of benign cartilage-capped tu-
mors, or exostoses, primarily on the long bones of af-
fected individuals (Solomon 1963). Patients with HME
are generally short in stature, with varying degrees of
orthopedic deformity, and surgery may be required to
alleviate secondary complications such as joint pain and
restricted movement. Both hereditary and sporadic cases
of exostoses are linked to two main loci, EXT1 (EXT1
[MIM 133700]) on chromosome 8q24.1 (Cook et al.
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1993; Lu¨decke et al. 1995) and EXT2 (EXT2 [MIM
133701]) on chromosome 11p11-p12 (Wu et al. 1994;
Wuyts et al. 1995), although linkage to another locus,
EXT3 (EXT3 [MIM 600209]), on chromosome 19p has
also been described (Le Merrer et al. 1994). Chondro-
sarcomas develop in 0.5%–3% of cases (Schmale et al.
1994; Luckert-Wicklund et al. 1995), apparently be-
cause of loss of heterozygosity (LOH) at one or several
EXT loci, possibly in combination with additional LOH
at other, nonrelated sites (Raskind et al. 1995). Insofar
as mutation and, presumably, loss of function of either
EXT1 or EXT2 appears to be sufficient for tumor for-
mation, it has been suggested that these proteins are
tumor suppressors (Hecht et al. 1995; Lu¨decke et al.
1995; Raskind et al. 1995; Bove´e et al. 1999).
HumanEXT1 andEXT2 have both been cloned (Ahn
et al. 1995; Stickens et al. 1996; Wuyts et al. 1996), as
have homologs in rodents (Clines et al. 1997; Lin and
Wells 1997; Lohmann et al. 1997; Stickens and Evans
1997; Wei et al. 2000), Drosophila melanogaster (Bel-
laiche et al. 1998) and Caenorhabditis elegans (Clines
et al. 1997; Lohmann et al. 1997). Both EXT1 and
EXT2 belong to a larger family of homologous genes,
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the EXT family of putative tumor-suppressor genes, for
which three additional members have been cloned, the
EXT-like genes, EXTL1-3 (Wise et al. 1997; Wuyts et
al. 1997; Saito et al. 1998; Van Hul et al. 1998). In
humans, the corresponding EXT proteins, exostosin-1
(EXT1) and exostosin-2 (EXT2) are ubiquitously ex-
pressed glycoproteins of 746 and 718 amino acids, re-
spectively (Ahn et al. 1995; Stickens et al. 1996; Wuyts
et al. 1996). EXT1 and EXT2 have a predicted type II
transmembrane glycoprotein structure, and both pro-
teins localize predominantly to the endoplasmic retic-
ulum when overexpressed in cells (Lin and Wells 1997;
McCormick et al. 1998; McCormick et al. 2000).
Despite extensive genetic characterization, the func-
tion of the EXT proteins remained unknown until 1998,
when the study of a HS-deficient cell line, sog9, revealed
that EXT1 is involved in HS biosynthesis (McCormick
et al. 1998). Biochemical studies have since confirmed
that EXT1 and EXT2 both possess the N-acetylglucos-
amine (GlcNAc) and D-glucuronic acid (GlcA) trans-
ferase (T) activities representative of an HS-polymerase
(HS-Pol) (Lind et al. 1998; Senay et al. 2000; Wei et al.
2000). Moreover, the related protein EXTL2 encodes
a functionally related enzyme, a1,4-N-acetylhexosa-
minyltransferase (Kitagawa et al. 1999). It is proposed
that EXTL2 initiates HS-chain formation by transfer-
ring the first GlcNAc residue to a specific tetrasaccharide
linker sequence on the HS proteoglycan core protein
thereby providing the substrate for polymerization by
EXT1 and EXT2. By contrast, a recent study of C.
elegans EXT homologs suggests that a single protein,
Rib-2, most closely related to the human EXTL3 gene
product, is able to carry out both the HS-chain initiation
and polymerization steps, indicating that the biosyn-
thetic mechanism of HS in C. elegans is distinct from
that reported for the mammalian system (Kitagawa et
al. 2001). Surprisingly, the human EXTL3 gene encodes
a molecule with a strikingly different function, the cell-
surface receptor for Reg, which is a pancreatic b-cell
regeneration factor (Kobayashi et al. 2000a). Further,
most recently it has been suggested that EXTL3 may
modulate TNF-a induced NF-kB activity (Mizuno et al.
2001).
Recent data indicates that EXT1 and EXT2 form a
heterooligomeric complex in vivo that leads to an ac-
cumulation of both proteins in the Golgi apparatus (Ko-
bayashi et al. 2000b; McCormick et al. 2000). In agree-
ment with this, in situ hybridization studies in themouse
show identical expression patterns for EXT1 and EXT2
mRNA (Stickens et al. 2000). In vivo functional assays
have shown that EXT2 cannot substitute for EXT1 in
either sog9 (McCormick et al. 2000) or CHO cell sys-
tems (Wei et al. 2000). Moreover, the Golgi-localized
EXT1/EXT2 complex was found to possess substan-
tially higher glycosyltransferase activity than EXT1
alone, suggesting that this complex represents the bio-
logically relevant form of the HS-Pol enzyme (McCor-
mick et al. 2000). These findings have since been con-
firmed in a yeast cell system, which has the advantage
of not exhibiting any endogenousHS-Pol activity (Senay
et al. 2000). This heterooligomeric model of the HS-
Pol provides a rationale to explain how inherited mu-
tations in either of the two EXT genes can cause loss
of HS biosynthesis activity, resulting in HME (McCor-
mick et al. 2000). Recently, a study involving HS-de-
ficient mutant CHO cells similarly rescued by human
EXT1 expression, localized the GlcA-T catalytic do-
main to the N-terminal side of the central region of the
EXT1 protein (Wei et al. 2000). The importance of HS
for normal growth and development, and therefore the
importance of EXT1, has also been demonstrated in
several in vivo models, including Drosophila (Bellaiche
et al. 1998; The et al. 1999; Toyoda et al. 2000), and
the mouse (Lin et al. 2000), as well as in primary cell
culture of HME diseased chondrocytes (Bernard et al.
2000; Legeai-Mallet et al. 2000). Moreover, the link
between EXT and HME has been further affirmed by
a study showing that exostosin expression was signifi-
cantly reduced—and, in some cases, absent—in HME-
derived chondrocytes (Bernard et al. 2001).
Extensive genetic analysis of HME patients’ genomic
DNA over the past few years has led to the identification
of a number of mutations in both EXT1 and EXT2 that
appear to be disease related, the majority of which result
in premature termination. However, a small number of
mutations have been identified—often repeatedly—
affecting single amino acids, mainly in the N-terminal
half of the EXT1 and EXT2 proteins (Wuyts and Van
Hul 2000). Here, a functional assay that detects HS
expression in EXT1-deficient cells, was used to test pu-
tative etiological mutant EXT1 proteins for their ability
to rescue HS biosynthesis in vivo. Of the 12 reported
etiological missense mutations, 4 exhibited EXT1 HS-
Pol activity in this assay. Moreover, anion-exchange
chromatography confirmed the presence of HS on the
surfaces of cell lines stably expressing these mutant pro-
teins, indicating that the herpes simplex virus (HSV)-
infectivity assay is a reliable indicator of HS biosyn-
thesis. Three of these four “active” mutations affect
amino acids that are not conserved among vertebrates
and invertebrates, whereas all of the HS-biosynthesis
null mutations affect only conserved amino acids. Fur-
ther, substitution or deletion of each of these four “non-
essential” residues does not eliminate HS expression.
Taken together, these results indicate that several of the
reported etiological mutants retain the ability to syn-
thesize and express HS on the cell surface. The corre-
sponding missense mutations may therefore represent
rare genetic polymorphisms in the EXT1 gene or may
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interfere with as yet undefined functions of EXT1 that
are involved in HME pathogenesis.
Material and Methods
Cells, Virus, and DNA
The origin of the HS-deficient murine sog9 cell line
has been described elsewhere (Banfield et al. 1995), as
has their specific defect in the EXT1 gene (McCormick
et al. 2000). Cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) (Life Technologies) with 10%
fetal bovine serum (Life Technologies). Stable cell lines
were generated by transfection using LipofectAMINE
PLUS reagent (Life Technologies), followed by selection
in media supplemented with 700 mg/ml Geneticin (G-
418 Sulfate) (Life Technologies). The HS-deficient mu-
tant Chinese hamster ovary (CHO) cell line, pgsD-677,
bearing a specific defect in the EXT1 gene (Wei et al.
2000) has been described previously (Lidholt et al.
1992). These cells were maintained in Ham’s F12 me-
dium supplemented with 7.5% fetal bovine serum (Hy-
clone Laboratories). The three additional CHO cell lines
were generously provided by Dr. Stephen H. Leppla
(Gordon et al. 1995). The wild-type and furin-deficient
(FD11) CHO cells were maintained in DMEM/F12
(1:1) (Life Technologies) supplemented with 5% fetal
bovine serum. The stably transfected FD11furin#5-1
CHO cells, were grown in the same medium supple-
mented with 400 mg/ml Geneticin. A mutant HSV-2
strain, L1BR1, which has a modified b-galactosidase
gene inserted into the US3 protein kinase gene under the
control of the HSV-1 beta 8 promoter (Nishiyama et
al. 1992) was obtained as a generous gift from Y. Ni-
shiyama. Two commercially available mammalian ex-
pression vectors were used for all EXT constructs:
pcDNA3.1myc-his (Invitrogen) and pEGFP-N1 (Clon-
tech). All DNA was amplified in Escherichia coli DH5a
(Life Technologies) and was prepared for transfection
using standard plasmid purification systems (Qiagen and
Life Technologies).
Construction of EXT1 Etiological Mutant Proteins
All EXT mutants were constructed by site-directed
PCR mutagenesis using the previously described wild-
type EXT1 constructs, pEXT1myc-his and pEXT1gfp
(McCormick et al. 1998; McCormick et al. 2000). It
should be noted that the sequence of the human EXT1
gene in pEXT1myc-his has been found to differ from
the published sequence caused by both silent mutations
(672ArG, 1062CrT, 1326TrC, 1431CrT, 1650TrC, and
1761GrA) and missense mutations (180GrCrE60D,
181CrGrP61A, and 1240GrTrA413S). However, these
mutations are phenotypically silent, as they are present
in both wild-type and mutant constructs. All oligonu-
cleotide primers (table 1), Taq DNA polymerase and
restriction enzymes were obtained from Life Technolo-
gies, unless otherwise stated.
The Q27K, D164H, N316S, A486V, and P496L eti-
ological mutants, as well as the corresponding conserved/
severe change and deletion mutants, were constructed
following Stratagene’s QuikChange site-directed muta-
genesis protocol. In brief, complementary oligonucleo-
tides bearing the desired mutation were used to PCR
amplify the entire pEXT1gfp plasmid, using Pfu Turbo
DNA polymerase (Stratagene). The parental DNA tem-
plate was then digested withDpnI and the nicked vector
DNA bearing the desired mutation was transformed di-
rectly into E. coli competent cells. The R280G, R280S,
R340S, R340H, R340L, and repaired H340R mutants
were all constructed by PCR amplification using mu-
tagenic primers, followed by cloning into pEXT1myc-
his, using appropriate restriction enzymes.
The single-codon deletion at position H627 was in-
troduced by way of a two-step PCR mutagenesis strat-
egy, using an overlapping and complementary primer set,
bearing the 3-bp deletion, and two external primers.
First, fragments were made with an ∼40 bp overlap in
the region that included the 3-bp deletion, then the two
overlapping PCR fragments were denatured, were an-
nealed together, were extended for 15 min with Taq
polymerase, and were amplified by PCR, using the out-
ermost primers to make a fragment which was cloned
into the pEXT1myc-his vector.
To convert from myc epitope tags to green fluorescent
protein tags, all EXT1 mutants were excised from the
pEXT1myc-his vector, with BamHI and SacII, and were
religated into the BglII and SacII sites of the pEGFP-N1
vector, such that they were in frame for an EXT1-gfp
fusion protein.
HSV-Infectivity Assay for EXT1 Function
The in vitro transfection/infection assay was per-
formed in sog9 cells, as described elsewhere (McCormick
et al. 1998), using the HSV-2 strain L1BR1.
FGF-2-Based Assay for HS Cell-Surface Expression in a
CHO Cell System
Binding of biotinylated basic fibroblast growth factor
(FGF-2) was measured by fluorescence-activated cell
sorting, as described elsewhere (Bai et al. 1999).
Anion-Exchange Chromatography of Cell-Surface
Glycosaminoglycans
Anion-exchange HPLC was performed, as described
elsewhere (McCormick et al. 1998), using stably trans-
fected cell lines.
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Table 1
Oligonucleotide Primers Used for PCR Mutagenesis of EXT1a
Primer
DNA Sequence
(5′r3′)
Q27K (forward) TTTTATTTCGGAGGCCTGAAGTTTAGGGCATCG
Q27K (reverse) CGATGCCCTAAACTTCAGGCCTCCGAAATAAAAC
Q27A (forward) TTTTATTTCGGAGGCCTGGCGTTTAGGGCATCG
Q27A (reverse) CGATGCCCTAAACGCCAGGCCTCCGAAATAAAAC
Q27del (forward) TTTTATTTCGGAGGCCTGTTTAGGGCATCG
Q27del (reverse) CGATGCCCTAAACAGGCCTCCGAAATAAAAC
D164H (forward) CTGGATACTTTAGACAGACACCAGCTGTCACCTCAGTATGTG
D164H (reverse) CACATACTGAGGTGACAGCTGGTGTCTGTCTAAAGTATCCAG
D164E (forward) CTGGATACTTTAGACAGAGAACAGCTGTCACCTCAGTATGTG
D164E (reverse) CACATACTGAGGTGACAGCTGTTCTCTGTCTAAAGTATCCAG
D164del (forward) CTGGATACTTTAGACAGACAGCTGTCACCTCAGTATGTG
D164del (reverse) CACATACTGAGGTGACAGCTGTCTGTCTAAAGTATCCAG
R280G (forward) GGAAGAGGTACCTGACAGGGATAGGATCAGACACCGGGAATGCCTTATATC
R280S (forward) GGAAGAGGTACCTGACAGGGATAGGATCAGACACCAGCAATGCCTTATATC
R280 (reverse) GAGTTATCCCAGAAGTGGCTGCGCGCGGGGTACCCACAATCCTCTCAGG
N316S (forward) CACAAGGATTCTCGCTGCGATCGAGACAGCACCGAGTATGAGAAG
N316S (reverse) CTTCTCATACTCGGTGCTGTCTCGATCGCAGCGAGAATCCTTGTG
N316a (forward) CACAAGGATTCTCGCTGCGATCGAGACGCCACCGAGTATGAGAAG
N316A (reverse) CTTCTCATACTCGGTGGCGTCTCGATCGCAGCGAGAATCCTTGTG
N316del (forward) CACAAGGATTCTCGCTGCGATCGAGACACCGAGTATGAGAAG
N316del (reverse) CTTCTCATACTCGGTGTCTCGATCGCAGCGAGAATCCTTGTG
R340 (forward) CGGGATCCCGCAGGACACATGCAGGCCAAAAAACGCTATTTCATCC
R340S (reverse) CAAAGCCTCCAGGAATCTGAAGGACCCAAGCCTGCTACCACGAGGAACCAG
R340H (reverse) CAAAGCCTCCAGGAATCTGAAGGACCCAAGCCTGTGACCACGAGGAACCAG
R340L (reverse) CAAAGCCTCCAGGAATCTGAAGGACCCAAGCCTGAGACCACGAGGAACCAG
H340R (reverse) CAAAGCCTCCAGGAATCTGAAGGACCCAAGCCTGCGACCACGAGGAACCAG
A486V (forward) GCAGTCATCCATGTGGTGACGCCCCTGGTCTCTCAGTCC
A486V (reverse) GGACTGAGAGACCAGGGGCGTCACCACATGGATGACTGC
A486H (forward) GCAGTCATCCATCATGTGACGCCCCTGGTCTCTCAGTCC
A486H (reverse) GGACTGAGAGACCAGGGGCGTCACATGATGGATGACTGC
A486del (forward) GCAGTCATCCATGTGACGCCCCTGGTCTCTCAGTCC
A486del (reverse) GGACTGAGAGACCAGGGGCGTCACATGGATGACTGC
P496L (forward) CAGTCCCAGCTAGTGTTGAAGCTCCTCGTGGCTGCAGCC
P496L (reverse) GGCTGCAGACACGAGGAGCTTCAACACTAGCTGGGACTG
P496H (forward) CAGTCCCAGCACGTGTTGAAGCTCCTCGTGGCTGCAGCC
P496H (reverse) GGCTGCAGACACGAGGAGCTTCAACACGTGCTGGGACTG
P496del (forward) CAGTCCCAGGTGTTGAAGCTCCTCGTGGCTGCAGCC
P496del (reverse) GGCTGCAGACACGAGGAGCTTCAACACCTGGGACTG
H627 (forward 1) AGTATTCATCTTATCTGGGAG
H627 (reverse 1) GGTAGTGATAATATTTDGTAAATAGCAG
H627 (forward 2) TGACAGGAGCTGCTATTTACDAAATATT
H627 (reverse 2) TTTTCCTTTTGCGGCCGCTTTTTTCCTTAAGTCGCTCAATGTCTCGGTA
a Mutated nucleotides are underlined.
Results
In Vivo Analysis of Mutant EXT1 Function
Twelve etiological missense mutations and one single
codon deletion mutation have been identified in the
EXT1 gene of HME patients (table 2). These mutations
are found exclusively in the luminal portion of the pro-
tein in four of the eleven exons (fig. 1). To date, only
two of these missense mutations, G339D and R340C,
have been evaluated for HS biosynthetic activity in vivo
(McCormick et al. 1998). In this study, the 10 remaining
etiological missense mutants, affecting seven different
residues (Q27, D164, R280, N316, R340, A486, and
P496), were examined by way of the HSV-infectivity
assay and representative results for each of the seven
affected residues are shown in figure 2. Two types of
mutant EXT1 proteins were identified (fig. 1): “active”
mutants, which rescue HSV infectivity, and null mutants,
which are inactive in the HSV-infectivity assay, suggest-
ing that they have lost their ability to synthesize HS.
Table 2 summarizes in vivo HS biosynthetic activity for
all of the EXT1 missense mutants analyzed to date, as
well as for the single–amino acid–deletion mutant.
Residues G339 and R340 are of particular interest, in
that they are part of a RGRR motif (fig. 3), which is a
classic recognition site for cleavage by furin, a cellular
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Table 2
Functional Assay of EXT1 Proteins Bearing Mutations Implicated in
HME
Etiological
Mutation Reference(s)
HS
Biosynthesisa
wt EXT1 Ahn et al. (1995) b
Q27K Wuyts and Van Hul (2000) 
D164H Bove´e et al. (1999) 
R280G Raskind et al. (1998); Wuyts et al. (1998) 
R280S Raskind et al. (1998) 
N316S Bove´e et al. (1999) 
G339D Philippe et al. (1997) b
R340C Philippe et al. (1997); Dobson-Stone et al. (2000) b
R340S Wuyts et al. (1998) 
R340H Raskind et al. (1998); Dobson-Stone et al. (2000) 
R340L Hecht et al. (1997); Dobson-Stone et al. (2000) 
H340Rc … 
A486V Xu et al. (1999) 
P496L Xu et al. (1999) 
H627deld Raskind et al. (1998) 
a As measured by the HSV-infectivity assay (McCormick et al. 1998), inwhich
HS-deficient sog9 cells are transfected with EXT1 forms and then are challenged
with a b-galactosidase–expressing HSV strain.  p wild-type EXT1 level of
infectivity;  p background level of infectivity.
b As published elsewhere (McCormick et al. 1998).
c Repaired version of the R340H etiological mutant.
d del p deletion of the amino acid.
Figure 1 Two phenotypes for etiological EXT1 mutants. Sche-
matic representation of the EXT1 coding region, illustrating the 11
exons of the human EXT1 gene with all 12 of the currently reported
missense mutations from HME patients, and one single–amino acid
deletion. The two missense mutations analyzed prior to the current
study (McCormick et al. 1998) are indicated in italics. Mutant EXT1
forms can be divided into two categories: “active” mutants (top ar-
rows), which were observed to synthesize HS, and null mutants (bot-
tom arrows), which were observed to abrogate HS biosynthesis.
proprotein convertase (Lazure et al. 1998). To determine
whether furin is essential for HS biosynthesis, furin-ex-
pressing and furin-deficient CHO cell lines were chal-
lenged with HSV. However, the furin-deficient cells were
found to be as sensitive to HSV as wild-type cells (data
not shown), indicating that a lack of furin does not in-
hibit HS biosynthesis and transduction to the cell sur-
face. It is, therefore, unlikely that the etiologicalmissense
mutations affecting residues G339 and R340 inactivate
EXT1 through loss of a furin-recognition site.
To determine whether EXT proteins are able to com-
plement each other in trans, as has been observed for
a bacterial b-glycosyltransferase (Jing and DeAngelis
2000), all possible combinations of the null mutants
were cotransfected into sog9 cells and assayed for rescue
of HSV infectivity. No complementation was observed
(data not shown). Moreover, when sog9 cells were co-
transfected with mutant and wild-type forms of EXT1,
no measurable decrease in activity was observed, even
when mutant and wild-type forms were coexpressed in
a ratio of 10:1 (data not shown). These results indicate
that wild-type EXT1 is able to polymerize HS in the
presence of mutant forms of the EXT1 protein.
To further confirm that certain of the mutant EXT1
forms were indeed capable of inducing the cell-surface
expression of HS, a second in vivo cell culture assay
system was developed. In this assay, HS-deficient mutant
CHO cells, pgsD-677, were transfected with gfp-tagged
wild-type and mutant EXT1 proteins, and then tested
for their ability to bind basic fibroblast growth factor
(FGF2), a known ligand of HS (Bai et al. 1999). Results
in this alternate cell system confirmed the respective
“active” or null phenotypes observed with the HSV-in-
fectivity assay (table 2; fig. 1) for each of the mutant
constructs (data not shown).
Anion-Exchange Chromatography of Cell-Surface
GAGs
To investigate GAG synthesis directly, in sog9 cells
stably expressing mutant EXT1 proteins, anion-
exchange chromatography of radiolabeled cell-surface
GAGs was performed for each of the seven residues
analyzed in figure 2. The results, illustrated in figure 4,
show a single GAG peak corresponding to HS for each
of the “active” mutants, suggesting that these mutants
express HS to levels comparable to those of wild-type
EXT1. In agreement with their null phenotype in the
HSV-infectivity assay (fig. 1), none of the null mutant
forms could catalyze the polymerization of HS.
Characterization of “Active” EXT1 Etiological Mutants
The results so far indicated that four of the putative
etiological mutations retained significant HS biosynthe-
sis activity. One possibility to explain these results is that
these mutant forms of EXT1 possess reduced HS bio-
synthetic activity compared with wild-type forms. To test
this possibility, the four codons in EXT1 were subjected
to further alteration. As is summarized in table 3, sub-
stitution of the acidic Q27 or N316 residues by alanine,
an unrelated aliphatic residue, did not inactivate HS-Pol
activity. Likewise, substitution of the uncharged A486
and P496 residues by a basic, positively charged histidine
residue did not abolish HS biosynthesis. Remarkably,
HS expression was retained even when the affected
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Figure 2 Cell-culture assay for EXT1 function. HSV-resistant,
HS-deficient mouse fibroblast sog9 cells either were mock-transfected
or were transfected with cDNAs corresponding to wild-type or mutant
EXT1 constructs. Cells were then infected with a b-galactosidase ex-
pressing HSV and were stained blue with X-gal. For the two residues
affected by multiple etiological missense mutations (R280 and R340)
only one mutant form is shown.
amino acid was deleted from the EXT1 protein. Taken
together, the data show that these four amino acid res-
idues are not essential for the HS-Pol activity of EXT1.
An Aspartate Residue Required for HS-Pol Activity
The inactivating missense mutation D164H, located
in a DXD sequence (fig. 3), was also subjected to further
mutagenic analysis. DXD motifs, and aspartate residues
in particular, have been reported to be important com-
ponents of catalytic sites for glycosyltransferase activity
(Busch et al. 1998; Wiggins and Munro 1998). The eti-
ological change from aspartate to histidine represents a
severe change from an acidic to a basic amino acid. To
determine whether there was an absolute requirement
for aspartate, as has been described for other glycosyl-
transferase enzymes (Busch et al. 1998; Griffiths et al.
1998; Wiggins and Munro 1998; Jing and DeAngelis
2000), the aspartate residue was replaced by the closely
related amino acid, glutamate, in the otherwise wild-
type EXT1 protein. This mutant form was also defective
in HS polymerization, suggesting that EXT1 requires an
aspartate residue at position 164 for HS-Pol function.
Discussion
Although the pathogenesis of HME was first described
nearly 200 years ago (see Solomon 1963), it is only in
the past few years that elegant genetic analyses (Ahn et
al. 1995; Stickens et al. 1996; Wuyts et al. 1996) and
intensive biochemical studies (Lind et al. 1998; McCor-
mick et al. 1998) have permitted the identification and
functional characterization of the exostosin family of
putative tumor-suppressor proteins. The HSV assay em-
ployed in this study is useful for evaluating in vivo HS-
Pol activity, as it measures the biosynthesis and cell-
surface expression of HS—unlike in vitro enzyme assays,
which measure the addition of a single sugar to an ar-
tificial substrate. It is highly specific, because it was used
to show that EXT2 is distinct from EXT1 (McCormick
et al. 2000), despite the fact that EXT2 has been shown
to possess the same glycosyltransferase activities as
EXT1 in vitro (Lind et al. 1998; Kitagawa et al. 2001;
Senay et al. 2000). In the present study, we evaluated
the effect on in vivo HS-Pol activity of HME etiological
mutations identified in the EXT1 locus of affected in-
dividuals, and we found that not all mutations were
inactivating. These results raise the possibilities that
these mutations are not related to disease pathogenesis
and that EXT1 possesses additional functions not yet
identified.
For other known glycosyltransferases, domain swaps
and site-directed mutagenesis have often proven to be
powerful tools for identification of key amino acids in-
volved in enzyme-substrate specificity and catalytic-site
activity (Xu et al. 1996; Seto et al. 1997; Hagen et al.
1999; Jing and DeAngelis 2000). In the case of the ex-
ostosin proteins, it is most likely that naturally occur-
ring etiological missense and single-codon deletion mu-
tations affect key functional domains, thereby providing
us with a subset of candidates for elucidating enzyme
function. Indeed, the results of theHSV-infectivity assay,
published previously (McCormick et al. 1998) and
presented here, have confirmed that eight previously
reported HME-linked missense mutations and one
single–amino acid–deletion mutation abolish enzyme
function in vivo. All of these mutations affect amino
acid residues that have been evolutionarily conserved,
among both vertebrate and invertebrate species (fig. 3),
suggesting that they are critical for EXT1 function. By
contrast, three of the four remaining missense muta-
tions—which do not inhibit HS expression in vivo—
affect residues that are not conserved among distantly
related eukaryotes. These amino acids are not essential
for EXT1 function in polymerizing HS in cultured cells,
as they can be deleted from the protein without incur-
ring loss of HS-Pol function. The possibility that these
mutants retain partial activity, producing an amount
and/or type of HS sufficient for HSV entry but insuf-
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Figure 3 Amino acid–sequence alignment for three EXT1 homologs: human EXT1 (GenBank accession number S79639); Ttv, from
Drosophila melanogaster (GenBank accession number AF083889) and Rib-1, fromCaenorhabditis elegans (GenBank accession numberU94834).
The putative transmembrane (TM) domains are labeled, predicted N-linked glycosylation sites are shaded in gray, conserved amino acids are
indicated by black boxes, and putative etiological EXT1 missense mutations are highlighted in yellow. Murine EXT1 (not shown) is 99% similar
to hEXT1 at the amino acid level (Lohmann et al. 1997) and is identical to hEXT1 at all of the etiological mutation positions highlighted in
yellow. Alignments were predicted and visualized using ClustalW 1.8 and Boxshade 3.21 software.
ficient for proper bone development, cannot be
excluded.
The one exception, N316S, is conserved (fig. 3) and
lies directly next to a putative glycosyltransferase cat-
alytic site motif, DXD (Busch et al. 1998; Wiggins and
Munro 1998), which is itself, however, not totally con-
served (fig. 3). The fact that alteration and even deletion
of N316 does not eliminate HS biosynthesis is intrigu-
ing, if this particular DXD motif is the catalytic site for
GlcA-T activity, as has been proposed elsewhere (Wei
et al. 2000). D164H also lies within a DXD motif (fig.
3). Furthermore, D164 appears to be highly sensitive to
mutation, as even a very conserved amino acid substi-
tution was observed to abrogate HS biosynthesis. It has
been proposed thatDXDmotifs correspond to nucleotide
and cation binding domains critical to catalysis (Busch
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Figure 4 Anion-exchange chromatography of cell-surface
GAGs. Sog9 cells, and sog9 cells stably transfected with the indicated
EXT1 forms, were grown for 24 h in the presence of 35SO4 (20 mCi/
ml). GAGs were isolated and fractionated by HPLC. The elution po-
sition of HS is indicated by a horizontal bar. For the two residues
affected by multiple etiological missense mutations (R280 and R340),
only one mutant form is shown.
Table 3
Functional Assay of EXT1 Proteins Bearing Selected Mutations
Etiological
Mutation
New
Mutation
Nature
of Change
HS
Biosynthesisa
Q27K Q27A Severe 
Active Q27P Severe 
Q27del Deletion 
D164H D164E Conserved 
Null D164del Deletion 
N316S N316A Severe 
Active N316del Deletion 
A486V A486H Severe 
Active A486del Deletion 
P496L P496H Severe 
Active P496del Deletion 
a  p wild-type EXT1 level of infectivity;  p background level
of infectivity.
et al. 1998; Wiggins and Munro 1998), and it is there-
fore possible that D164may play a key role in catalyzing
HS polymerization. It will be interesting to determine
whether mutation of aspartates 162, 164, 313, and/or
315 specifically abolishes either GlcA-T or GlcNAc-T
activities.
The inactive H627 deletion mutant is of particular
interest because this mutation is located in the C-ter-
minus of the protein, which is highly conserved among
exostosin family members and appears to interfere with
specific protein-protein interactions in yeast and mam-
malian two-hybrid systems (Simmons et al. 1999). It is
possible that this amino acid residue is involved in
GlcNAc-T activity, although it does not complement
specific defects in GlcA-T activity caused by mutations
at residues 339 and 340. In vitro enzyme analysis and
coimmunoprecipitation assays will be required to de-
termine whether H627 affects HS synthesis directly, by
eliminating GlcNAc-T activity, or whether it affects
protein-protein interactions, such as oligomerization, or
chaperone-mediated folding of EXT1.
Interestingly, 7 of the 12 reportedmissensemutations,
all of which have the null phenotype, are found in two
clusters, at position R280 and around positions G339
and R340 (fig. 1), suggesting that these regions may
harbor key elements for EXT1 function. Indeed, in vitro
enzyme-assay analysis of two of these missensemutants,
G339D and R340C, has previously revealed that mu-
tation of these residues selectively abrogates GlcA-T
activity but not GlcNAc-T activity (McCormick et al.
2000). Moreover, missense mutations recently found in
the same region, in hamster EXT1, also selectively alter
GlcA-T activity, suggesting that this region of the pro-
tein contains an essential element of the GlcA-T cata-
lytic domain (Wei et al. 2000).
The autosomal dominant–inherited pattern of HME
would suggest that one mutant copy of the gene would
be sufficient to cause disease. However, no dominant
negative phenotype was observed, consistent with a pre-
vious report (Wei et al. 2000). This is a rather surprising
result, in light of the ability of the EXT proteins—both
wild-type and mutant—to form homooligomers and
heterooligomers in vivo (Kobayashi et al. 2000b; Mc-
Cormick et al. 2000). This implies that oligomer for-
mation may require only one functional copy of EXT1
for the oligomer to retain its function. Alternatively,
observed HS-Pol activity may be caused by a subset of
totally functional heterooligomers, as it is likely that,
in any cell, there are three types of oligomers: those
containing only wild-type copies of EXT1, those con-
taining copies of both wild-type and mutant EXT1 pro-
teins, and those composed of only mutant proteins.
Taken together, these results suggest that, at the cellular
level, one functional copy of the EXT1 gene is sufficient
for activity, an idea that is in agreement with the two-
hit model of tumorigenesis proposed for both sporadic
and HME-linked exostoses formation (Mertens et al.
1994; Hecht et al. 1995; Raskind et al. 1995; Bove´e et
al. 1999).
Studies with the Drosophila homolog of EXT1, Ttv,
have shown that this protein is necessary for the dif-
fusion of Hh, a cell-signaling molecule that plays a key
role in fruit fly development (Bellaiche et al. 1998), and
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that Ttv is responsible for the bulk of HS biosynthesis
in this organism (The et al. 1999; Toyoda et al. 2000).
This discovery has proven interesting, in light of the fact
that the mammalian homolog of Hh, Indian Hedgehog
(Ihh), appears to play a key regulatory role in chon-
drocyte differentiation (Lanske et al. 1996; Vortkamp
et al. 1996). These results suggest a possible etiology
for HME pathogenesis, in which a lack ofHS expression
would interfere with the Ihh-mediated regulation of
chondrocyte maturation and, thus, with bone formation
(Bellaiche et al. 1998; Lin et al. 2000; Stickens et al.
2000). It is likely that an examination of the HS ex-
pression of etiological mutation-bearing chondrocytes
from HME patients will help to shed light on the mo-
lecular pathology of this disease.
In conclusion, we have shown that five of the amino
acids previously identified in HME patients/families are
critical for HS expression and that, remarkably, four
putative etiological missense mutants retain the ability
to synthesize HS. In fact, the four affected residues could
each be deleted from the EXT1 protein without causing
a detectable alteration in HS biosynthetic activity. These
results raise an important question about the link be-
tween HS synthesis and HME, for which at least three
possible explanations exist. First, EXT1 could harbor
additional activities not detectable by the HSV-infectiv-
ity assay. Second, it is possible that these reported mu-
tations may be rare genetic polymorphisms. In these
patients, the HME phenotype could be caused by un-
identified mutations present in the noncoding regions of
the EXT genes, such as introns or enhancer and/or pro-
moter regions, which could influence EXT1 mRNA-
expression levels. Alternatively, these patients could
bear mutations in the EXT3 or EXTL loci. Third, some
of the mutations may partially suppress enzyme activity,
but the residual catalytic capacity is sufficient to drive
HS synthesis in vivo. The use of the HSV-infectivity
assay to analyze possible roles for the 5′ and 3′ untrans-
lated regions of HME-derived EXT1 cDNAs, as well as
in vitro enzyme assays and coimmunoprecipitation as-
says with the existing EXT1 etiological mutant proteins
should help to distinguish among these possibilities.
Taken together, the data suggest that the link between
EXT activity and HME is more complex than first
thought. Determination of the role of HS in bone for-
mation—and, perhaps more importantly, of whether
EXT proteins harbor additional functions—should help
to further our understanding of the molecular patho-
genesis of HME.
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